Prevalence and clinical associations with premature ovarian insufficiency, early menopause, and low ovarian reserve in systemic sclerosis

Jutiviboonsuk, Arporn; Salang, Lingling; Eamudomkarn, Nuntasiri; Mahakkanukrauh, Ajanee; Suwannaroj, Siraphop; Foocharoen, Chingching

doi:10.1007/s10067-020-05522-5

Cited by 15 publications

(22 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CP is a strong oxidant that can promote oxidative stress in the ovaries, thereby inducing granular cell apoptosis. 24 Combined with clinical relevance, high cumulative doses of CP was one of the main causes of the prevalence of early menopause. 25 Oxidation and antioxidation indices were tested through a pre-test study.…”

Section: Discussionmentioning

confidence: 99%

Protective effect of small peptides from Periplaneta americana on cyclophosphamide‐induced premature ovarian failure

Wang

et al. 2021

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim: To investigate the protective effect of small peptides from Periplaneta americana (SPPA) on cyclophosphamide (CP)-induced premature ovarian failure (POF) in mice. Silent mating type information regulation 2 homolog 1 (SIRT1) /tumor-associated protein 53 (p53) signaling pathway plays an important role in delaying POF. Hematopoietic progenitor cell antigen (CD34) reflects ovarian aging from the side. However, whether SPPA inhibits POF in mice by influencing the SIRT1/p53 pathway and CD34 expression remains to be studied. Methods: Forty female Kun Ming (KM) mice were divided into four groups: a control group (normal saline, n = 10), POF model group (160 mg/kg CP, n = 10), SPPA low-dosage group (160 mg/kg CP + 100 mg/kg SPPA, n = 10), and SPPA high-dosage group (160 mg/kg CP + 200 mg/kg SPPA, n = 10). CP administration route is intraperitoneal injection, and SPPA administration route is intragastric. Eyeball enucleation blood samples and the ovaries of mice were collected by midline laparatomy and oopherectomy, and the malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD), follicle-stimulating hormone (FSH), and anti-Müllerian hormone (AMH) concentrations were tested. Immunohistochemical tests for the expressions of SIRT1, p53, and CD34 were carried out. Finally, ovarian mRNA levels of SIRT1 and p53 were detected with real-time fluorescence quantification PCR (qRT-PCR).Results: A mouse model of POF was generated using 160 mg/kg of CP. Compared with POF group, we found that plasma NO, MDA, and FSH decreased, while AMH and SOD increased in the SPPA low-dose group. Compared with the POF group, the SPPA low-and high-dosage groups achieved significant growth in the number of primordial, primary, and total number of healthy follicles at all levels, but sharp reductions in the number of atretic follicles. In addition, we found downregulated protein and mRNA expression of SIRT1, and upregulated that of p53 were observed in ovarian tissues of treated mice with POF, in immunohistochemistry experiments and qPCR experiments. In contrast, high protein and mRNA expression of SIRT1, and low that of p53 were observed in SPPA treatment groups. And the results of CD34 protein expression were consistent with that of SIRT1. Conclusion: In total, SPPA significantly inhibited POF caused by CP in mice via activation of the SIRT1/p53 signaling pathway in the mouse ovary.

show abstract

Section: Discussionmentioning

confidence: 99%

Protective effect of small peptides from Periplaneta americana on cyclophosphamide‐induced premature ovarian failure

Wang

et al. 2021

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…The mean age at disease onset was 60.0 ± 2.3 years, while the mean disease duration was 5.5 ± 0.9 years. At the initial presentation, 22 of 30 (73.3%) had Raynaud's phenomenon, and 16 had mRSS > 10 points with a median mRSS of 11 (8)(9)(10)(11)(12)(13)(14)(15)(16)(17). Half of the patients (50%) had pulmonary fibrosis, and 46.7% had esophageal involvement.…”

Section: Patient Characteristicsmentioning

confidence: 99%

“…Other significant concerns include early menopause and low ovarian reserve. 10 There are no similar reports on male gonadal function in SSc.…”

Section: Introductionmentioning

confidence: 99%

“…[4][5][6][7] SSc might cause impairment of gonadal function in both males and females. [8][9][10][11][12] Premature ovarian failure, exemplifying female gonadal function, has been reported in female SSc patients, particularly in those receiving a high cumulative dose of cyclophosphamide. Other significant concerns include early menopause and low ovarian reserve.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and clinical associations with primary hypogonadism in male systemic sclerosis

Thepwiwatjit

Charoensri

Sirithanaphol

et al. 2022

Journal of Scleroderma and Related Disorders

Self Cite

View full text Add to dashboard Cite

Background: Systemic sclerosis may affect male and female fertility. Premature ovarian failure has been reported in female systemic sclerosis patients, but the effects on male fertility in systemic sclerosis have not been studied. Objectives: We aimed to determine the prevalence and clinical associations with primary hypogonadism among male systemic sclerosis patients. Methods: This was a cross-sectional pilot study, including 30 adult male systemic sclerosis patients attending the Scleroderma Clinic, Khon Kaen University. Testosterone deficiency symptoms were assessed using the Aging Males’ Symptoms Rating Scale, urological examination, and blood testing (for total testosterone, free testosterone, follicle-stimulating hormone, and luteinizing hormone). We excluded patients with congenital hypogonadism and any acquired disorders of the testes and genitalia. The definition of primary hypogonadism was based on the International Society for the Study of the Aging Male 2015 diagnostic criteria for hypogonadism. Results: Seven patients met the definition of primary hypogonadism—a prevalence of 23.3% (95% confidence interval: 9.9–42.3). The respective mean age and mean systemic sclerosis duration was 59.4 ± 11.9 and 5.5 ± 4.7 years. Older age at onset, high triglyceride level, and older age starting corticosteroid treatment were significantly associated with primary hypogonadism ( p = 0.02, 0.02, and 0.03, respectively). Systemic sclerosis subset, disease severity, and immunosuppressant use were not associated with primary hypogonadism among Thai male systemic sclerosis patients. Conclusion: Around one-quarter of male systemic sclerosis patients had primary hypogonadism. Elderly onset of systemic sclerosis, hypertriglyceridemia, and late corticosteroid treatment were risk factors for developing primary hypogonadism.

show abstract

“…COVID-19 is also emerging as a disease that potentially triggers autoimmunity, and this raises the case for severe and lasting effects on various systems, including reproductive capacity, as seen with several autoimmune rheumatic diseases [ 3 – 5 ]. Moreover, several new drugs being used to treat these conditions may potentially have a bearing on future fertility, a risk that remains largely unexplored [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 and fertility—at the crossroads of autoimmunity and thrombosis

et al. 2021

View full text Add to dashboard Cite

The SARS-CoV-2 virus is known to mediate attack via ACE-2 Receptor, thus having adverse effects on cardiovascular, respiratory, digestive and reproductive systems, the latter being an area of emerging concern, due to the associated impact on fertility, with potential for an outsized effect on population distribution and socioeconomic road map in subsequent years. This narrative review aims to put forth the current evidence of effect of SARS-CoV-2 on human fertility from a multipronged immunologic, haematologic, and gynaecologic perspective; highlighting the areas of contradiction and potential future measures. A literature search was conducted through the MEDLINE and SCOPUS databases to identify articles on the subject in English. Relevant information was extracted from around 300 articles for this review. The existing data give non-conclusive evidence about the impact of SARS-CoV-2 infection on fertility; however, a greater impact on male fertility as compared to females merits further exploration. However, reproduction and fertility is a key concern and considering the pandemic is prolonged, natural conception or ART require extra precautions. Supplementary Information The online version contains supplementary material available at 10.1007/s00296-021-04977-2.

show abstract

Prevalence and clinical associations with premature ovarian insufficiency, early menopause, and low ovarian reserve in systemic sclerosis

Cited by 15 publications

References 38 publications

Protective effect of small peptides from Periplaneta americana on cyclophosphamide‐induced premature ovarian failure

Protective effect of small peptides from Periplaneta americana on cyclophosphamide‐induced premature ovarian failure

Prevalence and clinical associations with primary hypogonadism in male systemic sclerosis

COVID-19 and fertility—at the crossroads of autoimmunity and thrombosis

Contact Info

Product

Resources

About